Roche Causes Stir With Tecentriq/Avastin/Chemo Lung Cancer Win

20 Nov 2017

There are no actual data yet but the news that the closely-watched IMpower 150 study met a goal of progression-free survival and showed 'encouraging' signs on the overall survival endpoint has made IO rivals sit up, especially Merck & Co.

Thumbs up — Roche's closely watched lung cancer trial has succeeded • Source: Shutterstock

Roche has received a major boost from a closely-watched trial looking at a combination of its PD-L1 inhibitor Tecentriq (atezolizumab), the blockbuster Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) which shows that the cocktail shows promise as initial treatment for people with advanced non-squamous non-small cell lung cancer.

The Swiss major has revealed no actual data from the IMpower150 trial but noted that the combo provided a statistically...